Top Tweets for #FierceTalksASH

over 3 years ago

@FiercePharma @Daver_Leukemia @mpndoc A6: targeting #RareDisease by surface or other molec markers (eg #CD123) including in ultra-rare malignancies (eg #MEK, #BRAF, #RET, #RAS ). In #MPNSM — JAKi + 2nd agent combos now being investigated in frontline clinical trials #FierceTalksASH @AaronGerds @GabyHobbs #ASH22

1

2

1

0

over 3 years ago

Q6: Last question of the day! 🎉 #FierceTalksASH @doctorpemm

1

3

0

over 3 years ago

@FiercePharma @NeoGenomics @MDAndersonNews #ASH22 CAR-T yes exciting, but still some barriers we must address. #FACT accreditation, local expertise & standardization;local infrastructure; facilities; output vs inpt; #CARTOX committees & monitoring tox @Lymphoma_Doc @LNastoupilMD @DrKrinaPatel @NitinJainMD #FierceTalksASH

0

2

0

over 3 years ago

Q5 #FierceTalksASH @doctorpemm

1

0

over 3 years ago

@FiercePharma @NeoGenomics @MDAndersonNews @MDmasarova @lane_andy @NitinJainMD @mpndoc @MullallyLab @mpdrc @PedsHemeDoc @RaajitRampal A4: so many more to highlight! Discovery of novel #mAB in #CALRm in #MPNSM @challenlab ; #ZANU vs #IBR Dr J Brown #LBA ;post-Tx CY based #bmtsm @sghmd @BldCancerDoc @hemedoc ;BLINA LBA & ALL advances by @DrHKantarjian ; MDS advances by Dr GGM @garciamanero #FierceTalksASH #ASH22

1

3

0

over 3 years ago

@FiercePharma @NeoGenomics @MDAndersonNews A4: our @MDAndersonNews will have some notable abstracts incl updates in ALL new approaches; AML triplet combinations in active development; and in my own areas of focus on #RareDisease such as long-term outcomes in both #BPDCN & #MPNSM @MDmasarova @lane_andy #FierceTalksASH

1

10

2

0

over 3 years ago

Q4 #FierceTalksASH @doctorpemm

1

2

0

over 3 years ago

@FiercePharma @NeoGenomics @MDAndersonNews @sanamloghavi @KMirza @Anand_88_Patel @NitinJainMD @JoeKhouryMD A3: sometimes tx options may depend on molecular genomic profiling. So we must strive to make these tests affordable and standardized across the 🌍 must have leadership & expertise from #hemepath #pathologists & development of local pathways. @sanamloghavi #FierceTalksASH #leusm

0

3

1

0

over 3 years ago

Q3 #FierceTalksASH @doctorpemm

1

3

0

over 3 years ago

@FiercePharma A2: future efforts may include #NKcell therapies and #ADCs including in AML & combos of cytotoxic + targeted + immune agents possibly.Our groups a#@MDAndersonNews #leusm & #lymsm & #bmtsm are leading in many of these areas actively particularly nice combos #FierceTalksASH #ASH22

0

2

3

0

over 3 years ago

Q2 #FierceTalksASH #ASH22 @doctorpemm

1

4

0

over 3 years ago

@FiercePharma A1 (cont’d) also future of these agents likely in rational combos, looking for longer PFS, increased OS, longer follow-up to ensure no new tox signals, investigation of timed-duration therapies, less side effects, emphasis rates of #MRD and other factors #FierceTalksASH #ASH22

0

2

1

0

over 3 years ago

@FiercePharma #ASH22 in both CLL and MCL we now have several #BTKi for our patients. IBR, ACALA, and now ZANU and PITRO in later stages of development. Several factors we must consider together : PFS,toxicity profile, consideration of cardiac tox, patient-centered aspects. #FierceTalksASH

1

9

1

0

over 3 years ago

Q1 #FierceTalksASH @doctorpemm

1

3

0

over 3 years ago

3...2...1 #FierceTalksASH officially starts NOW! Shoutout to @NeoGenomics for sponsoring this chat! 🎉 #ASH2022

over 3 years ago

One hour to go... #FierceTalksASH #ASH22

0

3

0

4

0

over 3 years ago

One hour to go... #FierceTalksASH #ASH22

0

3

0

over 3 years ago

Starting today at 4 pm ET! Join @FiercePharma and @doctorpemm from @MDAndersonNews for the #FierceTalksASH Twitter Chat. 🩸🧐 #ASH22

FiercePharma's tweet photo. Starting today at 4 pm ET! Join @FiercePharma and @doctorpemm from @MDAndersonNews for the #FierceTalksASH Twitter Chat. 🩸🧐 #ASH22 https://t.co/FFK8noQwes

0

2

0